Welcome to our dedicated page for DR REDDYS LABORATORIES SEC filings (Ticker: RDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DR REDDYS LABORATORIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DR REDDYS LABORATORIES's regulatory disclosures and financial reporting.
Dr. Reddy’s Laboratories’ Board met on May 12, 2026 and approved several governance and leadership changes. It re-appointed Dr. K P Krishnan as an Independent Director for a second five-year term from January 7, 2027 to January 6, 2032, subject to shareholder approval.
The Board also approved Mr. Srikanth Velamakanni as an Additional Director, categorized as an Independent Director, for five years from July 1, 2026 to June 30, 2031, and appointed Deloitte Haskins & Sells LLP as Statutory Auditors for five years starting after the 42nd AGM. M/s Sagar & Associates were re-appointed as Cost Auditors for FY 2026-27.
Mr. Sandeep Khandelwal, Global Generics India Head, was elevated to Senior Management Personnel and inducted into the Management Council effective May 12, 2026. Under his leadership, the India business has grown its topline from Rs 2,300 crore to Rs 7,000 crore and expanded EBITDA margins from 19 percent to 24 percent, while scaling to a USD 750 million operation across six countries.
Dr. Reddy’s Laboratories Limited disclosed its upcoming analyst and institutional investor interactions. Management plans to attend an HSBC investor conference in Mumbai from May 14–15, 2026, and a Bank of America conference in Singapore from May 18–19, 2026. Both engagements are in-person group meetings during full business-day time slots, and the company notes that these schedules may change based on exigencies for either the investors or the company.
Dr. Reddy’s Laboratories Limited has approved new employee stock option grants. The committee granted 8,16,119 Indian stock options under the 2018 ESOP and 3,76,115 ADR stock options under the 2007 ADR scheme, each with an exercise price of Rs. 1,293.90 per share.
Both grants are in line with SEBI Share Based Employee Benefits and Sweat Equity Regulations, 2021, and will vest 100% at the end of 3 years, providing long‑term equity incentives for eligible employees across Indian and ADR programs.
Dr. Reddy’s Laboratories reports that it has received a Notice of Compliance from Health Canada for its generic Semaglutide Injection, authorizing commercialization, sale and distribution in Canada. The approval covers 2 mg/pen and 4 mg/pen strengths at 1.34 mg/mL and does not have a fixed expiry date. Dr. Reddy’s states it is the first company to obtain market authorization for generic Semaglutide Injection in Canada and has launch preparations underway. The company highlights that GLP‑1 receptor agonist therapies such as Semaglutide are supported by extensive clinical evidence for improving glycemic control in adults with type 2 diabetes and notes that Canada is recognized as the world’s second‑largest market for Semaglutide.
Dr. Reddy’s Laboratories filed a Form 6-K to notify investors that it will release its Q4 and full-year FY26 results for the period ended March 31, 2026 on Tuesday, May 12, 2026, after a Board meeting.
The company will distribute the financial results through stock exchanges, media, its website, and email, and will host an earnings call on May 12, 2026 at 19:30 IST / 10:00 ET. An audio recording and transcript of the call, as well as a press meet presentation, will be made available on its website.
Dr. Reddy’s Laboratories filed a Form 6-K explaining the status of its Semaglutide Injection in Canada after a media report. The company confirms the news headline is accurate: it is still awaiting Health Canada’s approval, referred to as a Notice of Compliance, for this product.
Dr. Reddy’s notes that, as part of the ongoing regulatory review, it received Drug Identification Numbers (DINs) for Semaglutide Injection from Health Canada on April 22, 2026. The company states it remains engaged with the regulator and intends to bring the product to the Canadian market once approval is granted. It also clarifies that, at this stage, there is no material event or information requiring disclosure under Regulation 30 of the SEBI Listing Regulations.
Dr. Reddy’s Laboratories Limited submitted a Form 6-K stating that its Board of Directors will consider, among other items, a proposal for recommending a final dividend for FY 2025-26, if any. The company notes this update is in continuation of an earlier intimation dated March 23, 2026.
Dr. Reddy’s Laboratories Limited reports that its step-down wholly owned subsidiary, Dr. Reddy’s Laboratories LLC in Russia, has received a final penalty decision from the Interdistrict Inspectorate of the Federal Tax Service of Russia. The decision relates to Value Added Tax on marketing services reclassified as taxable services.
The Russian tax authority set the penalty at RUB 9.27 million (approximately INR 11.40 million), reduced from an originally quantified amount of RUB 20.09 million (approximately INR 24.50 million). The company states that this penalty has no material impact on its financials, operations or other activities.
DR REDDYS LABORATORIES LTD executive Munnirpallam Madhu Sundar Subramanian, Global Head of Quality and PV, filed an initial ownership report showing his current stake in the company. The Form 3 lists direct ownership of 35,600 Equity Shares, without indicating any recent purchase or sale activity.
Dr. Reddy’s Laboratories Limited has entered into an agreement to sell its entire shareholding in its wholly owned subsidiary Svaas Wellness Limited to Enspirit Technology Services Private Limited. The agreement and completion of the sale both occurred on April 7, 2026.
Svaas Wellness Limited reported turnover of Rs. 28.5 Crore in FY 2025, all from Dr. Reddy’s Laboratories Limited, representing about 0.09% of consolidated turnover. The sale consideration is INR 2.23 Cr, and Svaas Wellness Limited will cease to be a wholly owned subsidiary. The buyer is not part of the promoter group and the deal is not a related party transaction.